Corcept Therapeutics
$116.23Change from previous close: +1.93%Absolute change: +$2.20
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | 142 | 198 | 127 | 120 | — |
| Depreciation and amortization | 1.9 | 1.3 | 2.4 | 3.4 | — |
| Capital expenditure | -0.2 | -2.2 | -0.1 | -0.4 | — |
| Investing cash flow | 69.8 | -178 | 90.9 | -114 | — |
| Financing cash flow | -220 | -28.3 | -149 | -17.3 | — |
| Share repurchases | 0.0 | 0.0 | -145 | 0.0 | — |
| Effect of exchange rates | 1.4 | -0.2 | 0.4 | — | — |
| Net change in cash | -8.6 | -7.7 | 68.9 | -11.3 | — |
| Free cash flow | 142 | 196 | 127 | 120 | — |